Prospective, multicenter, open, uncontrolled trial to evaluate the time to bacterial eradication and key symptom relief in the treatment of acute bacterial maxillary sinusitis with moxifloxacin 400 mg QD

Trial Profile

Prospective, multicenter, open, uncontrolled trial to evaluate the time to bacterial eradication and key symptom relief in the treatment of acute bacterial maxillary sinusitis with moxifloxacin 400 mg QD

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Dec 2014

At a glance

  • Drugs Moxifloxacin (Primary)
  • Indications Acute sinusitis; Bacterial infections
  • Focus Therapeutic Use
  • Acronyms SPEED
  • Sponsors Bayer
  • Most Recent Events

    • 20 May 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top